AURORA, CO--(Marketwire - October 30, 2007) - Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, will report increased VITROCELL™ product sales for its fiscal year 2007, ending October 31. Sales increased about six-fold compared to 2006 and represent sales of human pancreatic cell lines and growth media optimized to support these cells. These products were sold through an existing distribution agreement and are primarily intended for use in biomedical research. Sales of VitroPlus II, a cell culture media, increased 50% over 2006 sales by volume, indicating continued usage of our cell lines by the research community. VitroPlus II is a proprietary liquid formulation developed by the Company for optimum growth of its cell lines. Also, there was an increase in sales of cell lines (~50% of the total increase) which indicates increased market demand for these novel human pancreatic cell lines. Our products are especially suited for research studies of stem cell self-renewal and differentiation.
